ReAlta Life Sciences Doses First Patient in Phase 2 STAR-Study of RLS-0071 for Hypoxic Ischemic Encephalopathy in Newborns

NORFOLK, Va.--(BUSINESS WIRE)--Aug 1, 2023--

Related Keywords

Norfolk ,Virginia ,United States ,Ulrich Thienel ,John Rickman ,Kenji Cunnion ,Realta Life Sciences Inc ,Drug Administration ,Realta Life Sciences ,European Medicines Agency ,Malta Life Sciences ,Realta Chief Medical Officer Kenji Cunnion ,Realta Chief Executive Officer ,Orphan Drug Designation ,Fast Track Designation ,Investor Contact ,Business Wire , ,